Skip to main content

Articles

ASCO 2019 - Chronic Lymphocytic Leukemia

Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory CLL/SLL in the DUO Trial

Lexicon Limbo: From “Healthspan” to “New Normal” and “Discharge”

David B. Nash, MD, MBA

Original Research

Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis

Jeffrey T. Guptill, MD, MA, MHS; M. Chris Runken, PharmD; Michael Eaddy, PharmD, PhD; Orsolya Lunacsek, PhD; Rupali M. Fuldeore, MS

Stakeholder Perspective

Enhanced Understanding and Management of Rare Diseases Can Reduce Costs, Improve Clinical Outcomes

James T. Kenney, RPh, MBA

Oncology, Original Research

Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases

Lonnie Wen, RPh, PhD; Adriana Valderrama, PhD; Mary E. Costantino, PhD; Stacey Simmons, MD

Original Research, Practice Management

Prevalence and Economic Burden of Epilepsy in the Institutionalized Medicare Fee-for-Service Population

Kathryn Fitch, RN, MEd; Xiaoyun Pan, MS, PhD; Jocelyn Lau, MPH; Tyler Engel, ASA, MAAA; Krithika Rajagopalan, MS, PhD

Tavalisse (Fostamatinib Disodium Hexahydrate) First Spleen Tyrosine Kinase Inhibitor Approved for Chronic Immune Thrombocytopenia

Breast Cancer, FDA Approvals, In the News, Oncology

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

FDA Approvals, In the News

Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation

Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy

Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation

Page 53 of 244
Results 521 - 530 of 2436